| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $74,000 | 2 | 6 |
Sells | $52,253,395 | 30 | 94 |
| Rothenberg Mace | director | 2 | $74,000 | 0 | $0 | $74,000 |
| Barry Douglas | General Counsel | 0 | $0 | 2 | $16,369 | $-16,369 |
| Beckman Daniella | Chief Financial Officer | 0 | $0 | 2 | $25,282 | $-25,282 |
| Crystal Adam | See Remarks | 0 | $0 | 2 | $43,866 | $-43,866 |
| Weber Barbara | Chief Executive Officer | 0 | $0 | 2 | $57,710 | $-57,710 |
| EcoR1 Capital, LLC | 10 percent owner | 0 | $0 | 2 | $8.44M | $-8.44M |
| Boxer Capital Management, LLC | See remarks | 0 | $0 | 4 | $20.12M | $-20.12M |
| Third Rock Ventures IV, L.P. | 10 percent owner | 0 | $0 | 16 | $23.55M | $-23.55M |
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Over the last 12 months, insiders at Tango Therapeutics, Inc. have bought $74,000 and sold $52.25M worth of Tango Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Tango Therapeutics, Inc. have bought $4.58M and sold $20.49M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rothenberg Mace (director) — $74,000.
The last purchase of 10,000 shares for transaction amount of $37,800 was made by Rothenberg Mace (director) on 2024‑11‑18.
| 2025-02-05 | Sale | Weber Barbara | Chief Executive Officer | 9,013 0.0087% | $3.16 | $28,494 | -41.79% | |
| 2025-02-05 | Sale | Crystal Adam | See Remarks | 6,851 0.0066% | $3.16 | $21,659 | -41.79% | |
| 2025-02-05 | Sale | Beckman Daniella | Chief Financial Officer | 3,948 0.0038% | $3.16 | $12,481 | -41.79% | |
| 2025-02-05 | Sale | Barry Douglas | General Counsel | 2,556 0.0025% | $3.16 | $8,081 | -41.79% | |
| 2025-02-04 | Sale | Weber Barbara | Chief Executive Officer | 9,778 0.0093% | $2.99 | $29,217 | -35.53% | |
| 2025-02-04 | Sale | Crystal Adam | See Remarks | 7,432 0.0071% | $2.99 | $22,207 | -35.53% | |
| 2025-02-04 | Sale | Beckman Daniella | Chief Financial Officer | 4,284 0.0041% | $2.99 | $12,801 | -35.53% | |
| 2025-02-04 | Sale | Barry Douglas | General Counsel | 2,774 0.0027% | $2.99 | $8,289 | -35.53% | |
| 2024-11-18 | Rothenberg Mace | director | 10,000 0.0098% | $3.78 | $37,800 | -23.61% | ||
| 2024-11-14 | Rothenberg Mace | director | 10,000 0.0088% | $3.62 | $36,200 | -29.08% | ||
| 2024-11-07 | Sale | EcoR1 Capital, LLC | 10 percent owner | 1.21M 1.1237% | $2.94 | $3.54M | +0.71% | |
| 2024-11-06 | Sale | EcoR1 Capital, LLC | 10 percent owner | 1.49M 1.3103% | $3.28 | $4.9M | -12.04% | |
| 2024-11-06 | Sale | Boxer Capital Management, LLC | See remarks | 3.08M 2.5882% | $3.14 | $9.67M | -12.04% | |
| 2024-10-25 | Sale | Boxer Capital Management, LLC | See remarks. | 633,000 0.6113% | $6.87 | $4.35M | -50.93% | |
| 2024-10-22 | Sale | Boxer Capital Management, LLC | See remarks | 250,000 0.2383% | $6.78 | $1.7M | -55.80% | |
| 2024-10-21 | Sale | Boxer Capital Management, LLC | See remarks | 625,000 0.5752% | $7.05 | $4.41M | -58.88% | |
| 2024-09-13 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 67,400 0.0631% | $10.53 | $709,756 | -70.67% | |
| 2024-09-05 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 75,000 0.0693% | $11.56 | $867,135 | -73.46% | |
| 2024-08-30 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 175,000 0.1601% | $11.60 | $2.03M | -73.75% | |
| 2024-08-27 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 25,000 0.0236% | $11.55 | $288,665 | -72.72% |
| Third Rock Ventures IV, L.P. | 10 percent owner | 16859075 15.5535% | $99.97M | 0 | 17 | |
| EcoR1 Capital, LLC | 10 percent owner | 10630736 9.8075% | $63.04M | 0 | 2 | |
| Boxer Capital Management, LLC | See remarks | 3610642 3.331% | $21.41M | 0 | 4 | |
| Weber Barbara | Chief Executive Officer | 1622251 1.4966% | $9.62M | 0 | 4 | |
| Crystal Adam | See Remarks | 158210 0.146% | $938,185.30 | 0 | 5 | |
| Beckman Daniella | Chief Financial Officer | 150284 0.1386% | $891,184.12 | 0 | 4 | |
| Barry Douglas | General Counsel | 66014 0.0609% | $391,463.02 | 0 | 4 | |
| Rothenberg Mace | director | 31250 0.0288% | $185,312.50 | 2 | 0 | |
| Boxer Capital, LLC | 8198642 7.5637% | $48.62M | 3 | 1 | +19.37% | |
| Davis Aaron I. | director | 7123642 6.572% | $42.24M | 3 | 0 | +36.79% |
| LEWIS JOSEPH | director | 7053642 6.5074% | $41.83M | 3 | 0 | +40.76% |
| BCTG Holdings, LLC | 10 percent owner | 4488450 4.1409% | $26.62M | 1 | 1 | +7.42% |
| MVA Investors, LLC | See remarks | 108793 0.1004% | $645,142.49 | 0 | 8 | |
| Calhoun Lesley Ann | director | 6250 0.0058% | $37,062.50 | 0 | 1 |
$28,907,358 | 35 | 41.41% | $628.44M | |
$94,912,877 | 34 | -7.15% | $725.33M | |
$169,638,586 | 22 | 30.82% | $624.46M | |
$121,137,864 | 20 | -8.38% | $712.89M | |
$6,280,187 | 19 | 6.80% | $580.51M | |
$49,750,490 | 17 | 37.19% | $640.89M | |
$21,945,105 | 15 | -26.51% | $690.44M | |
$103,194,328 | 13 | 9.02% | $688.25M | |
$92,357,691 | 12 | 87.24% | $586.49M | |
Tango Therapeutics, Inc. (TNGX) | $18,262,420 | 10 | 29.82% | $642.78M |
$94,976,497 | 10 | -10.72% | $647.52M | |
$1,580,951 | 9 | -14.18% | $656.57M | |
$135,543,039 | 9 | -5.28% | $680.69M | |
$49,539,396 | 8 | 46.38% | $684.6M | |
$4,706,376 | 8 | 42.30% | $731.22M | |
$94,000,000 | 7 | -20.84% | $571.13M | |
$3,200,000 | 5 | -11.36% | $617.2M | |
$1,746,565 | 4 | -29.05% | $584.15M | |
$13,900 | 1 | -39.25% | $607.14M |
| Increased Positions | 59 | +34.91% | 13M | +11.02% |
| Decreased Positions | 71 | -42.01% | 6M | -5.34% |
| New Positions | 17 | New | 8M | New |
| Sold Out Positions | 32 | Sold Out | 2M | Sold Out |
| Total Postitions | 157 | -7.1% | 122M | +5.68% |
| Trv Gp Iv, Llc | $25,457.00 | 15.61% | 16.86M | 0 | 0% | 2024-12-31 |
| Tcg Crossover Management, Llc | $16,211.00 | 9.94% | 10.74M | +11M | New | 2024-12-31 |
| Ecor1 Capital, Llc | $16,052.00 | 9.84% | 10.63M | -3M | -20.25% | 2024-12-31 |
| Boxer Capital Management, Llc | $15,675.00 | 9.61% | 10.38M | +10M | New | 2024-12-31 |
| Boxer Capital, Llc | $12,380.00 | 7.59% | 8.2M | 0 | 0% | 2024-09-30 |
| Nextech Invest Ltd. | $8,356.00 | 5.12% | 5.53M | 0 | 0% | 2024-12-31 |
| Gilead Sciences, Inc. | $7,330.00 | 4.5% | 4.85M | +5M | New | 2024-12-31 |
| Blackrock, Inc. | $6,088.00 | 3.73% | 4.03M | -346,491 | -7.91% | 2025-03-31 |
| Farallon Capital Management Llc | $6,040.00 | 3.7% | 4M | +4M | New | 2024-12-31 |
| Vanguard Group Inc | $6,018.00 | 3.69% | 3.99M | +339,922 | +9.32% | 2024-12-31 |